{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-30",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "0078-0846",
      "generic_name": "tisagenlecleucel",
      "labeler_name": "Novartis Pharmaceuticals Corporation",
      "brand_name": "KYMRIAH",
      "active_ingredients": [
        {
          "name": "TISAGENLECLEUCEL",
          "strength": "2000000 1/1"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "0078-0846-19",
          "description": "1 INJECTION, SUSPENSION in 1 BAG (0078-0846-19)",
          "marketing_start_date": "20170830",
          "sample": false
        }
      ],
      "listing_expiration_date": "20271231",
      "openfda": {},
      "marketing_category": "BLA",
      "dosage_form": "INJECTION, SUSPENSION",
      "spl_id": "2f1194f6-c6f6-4c4b-97b2-2735cb14a6b1",
      "product_type": "CELLULAR THERAPY",
      "route": [
        "INTRAVENOUS"
      ],
      "marketing_start_date": "20170830",
      "product_id": "0078-0846_2f1194f6-c6f6-4c4b-97b2-2735cb14a6b1",
      "application_number": "BLA125646",
      "brand_name_base": "KYMRIAH",
      "pharm_class": [
        "CD19 Receptor Interactions [MoA]",
        "CD19-directed Chimeric Antigen Receptor [EPC]",
        "CD19-specific Chimeric Antigen Receptor [CS]",
        "Genetically-modified Autologous T Cells [EPC]",
        "Increased T Lymphocyte Activation [PE]",
        "T Lymphocytes",
        "Cultured",
        "Autologous",
        "Genetically-modified [EXT]"
      ]
    }
  ]
}